Australia's most trusted
source of pharma news
Tuesday, 22 October 2024
Posted 21 October 2024 AM
Two companies have been given the thumbs up for their new drugs at the PBAC's September intracycle meeting while PD-1/PD-L1 inhibitor drug makers were delivered a bitter blow to their broad PBS listing proposals.
In a call for ground-breaking reform, MSD and BMS first submitted independent proposals to the December 2023 meeting for an "expanded listing to facilitate broad access to indications with current or future TGA registration".
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.